Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,301.20
(
0.70%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.83
(
-0.81%
)
Bitcoin
74,050.42
(
0.15%
)
News Focus
News Focus
Post# of 30493
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Bickema post# 14472

Tuesday, 04/18/2017 11:12:11 AM

Tuesday, April 18, 2017 11:12:11 AM

Post# of 30493
China’s prescription-drug market >$300B by 2020, says NVS CEO, Joe Jimenez:

https://www.bloomberg.com/news/articles/2017-04-18/novartis-predicts-growth-in-chinese-drug-market-will-accelerate

While foreign companies have historically had to wait several years to bring treatments already approved in other countries into China, the country is speeding up its review of new medicines to combat increasing rates of diseases like cancer and hepatitis.

NVS’ Votrient and Jakavi recently received approval in China.

See #msg-129896462 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now